Advanced Melanoma Patients See Potential to Extend Life with Drug Combination

June 2, 2014 5:14 PM

9 0

Advanced Melanoma Patients See Potential to Extend Life with Drug 
Combination

June 2, 2014 - The first long term follow-up results from a phase 1b immunotherapy trial combining drugs for advanced melanoma patients has shown encouraging results � long-lasting with high survival rates � researchers report. The one-year overall survival rate was 94% and the two-year rate was 88%. It is particularly good news for senior citizens, who are the most likely victims of this most aggressive skin cancer.

First author Mario Sznol, M.D., professor of medical oncology at Yale Cancer Center, is presenting the updated data at the 2014 annual conference of the American Society of Clinical Oncology (ASCO) in Chicago.

Read more

To category page

Loading...